Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, variant U1 small nuclear 32 (RNVU1-32) is a pseudogene that encodes a noncoding RNA similar to canonical human U1 small nuclear RNA (snRNA), which is a central component of the spliceosome and essential for pre-mRNA splicing[1][4][5]. The U1 snRNA family comprises both canonical snRNA genes and many processed noncoding RNA variants and pseudogenes dispersed throughout the genome. Historically considered nonfunctional, some variant or pseudogene copies (vU1 snRNAs) have been shown to be transcribed, processed, and incorporated into ribonucleoprotein complexes, potentially acting in regulatory roles influencing gene expression at the level of pre-mRNA processing in certain cellular contexts[5]. RNVU1-32 specifically is classified as a pseudogene and is not recognized as a therapeutic target; its biological significance is unclear, and it does not encode a protein or possess known receptor, enzyme, or transporter activity[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, variant U1 small nuclear 32 (RNVU1-32).